STI-9199 for COVID19 (disease)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
ProSciento, Inc., Chula Vista, CA
COVID19 (disease)+2 More
STI-9199 - Drug
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 2 global, randomized, double-blind, placebo-controlled study designed to investigate the safety and preliminary efficacy of intranasal STI-9199 in adults and adolescents who are COVID-19 positive with mild to moderate symptoms.

Eligible Conditions

  • COVID19 (disease)
  • COVID-19

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for COVID19 (disease)

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: Baseline through Day 30

Baseline through D15
Patient rated response
Baseline through Day 11
Change in viral load
Baseline through Day 15
Participant perceived disease progression
Baseline through Day 30
Rate of COVID-19-related medical visits
Day 30
Incidence of adverse events (AEs) (safety)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for COVID19 (disease)

Trial Design

2 Treatment Groups

STI-9199
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

24 Total Participants · 2 Treatment Groups

Primary Treatment: STI-9199 · Has Placebo Group · Phase 2

STI-9199
Drug
Experimental Group · 1 Intervention: STI-9199 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline through day 30
Closest Location: ProSciento, Inc. · Chula Vista, CA
Photo of california 1Photo of california 2Photo of california 3
2017First Recorded Clinical Trial
0 TrialsResearching COVID19 (disease)
7 CompletedClinical Trials

Who is running the clinical trial?

Sorrento Therapeutics, Inc.Lead Sponsor
45 Previous Clinical Trials
2,451 Total Patients Enrolled
Mike Royal, MDStudy DirectorSorrento Therapeutics, Inc.
27 Previous Clinical Trials
1,801 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must provide written informed consent/assent if a minor which includes signing the institutional review board/independent ethics committee approved consent form prior to participating in any study related activity.
You are willing and able to comply with study procedures and follow-up visits.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.